Sign inJoin waitlistJoin the waitlist

Marlana Orloff

Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY

Credentials: · · ·

History

Thomas Jefferson University Hospital
2012–2014
Internal Medicine
Thomas Jefferson University Hospital
2009–2012
Penn State College of Medicine
2005–2009

Research

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
New England Journal of Medicine · 2021 · 741 citations
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint…
Journal for ImmunoTherapy of Cancer · 2022 · 311 citations
CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
Review · Retina · 2018 · 274 citations

TS
Takami Sato
21 papers
RC
Richard Carvajal
11 papers
Rino Seedor
11 papers · 3 as a fellow
AS
Alexander Shoushtari
9 papers
Carol Shields
8 papers
David Eschelman
8 papers
Omid Hamid
8 papers
April Salama
6 papers
JS
Jerry Shields
6 papers
Ryan Sullivan
6 papers · 1 as a fellow
John Kirkwood
5 papers
MM
Michael Mastrangelo
5 papers

Clinical trials

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Principal investigator · Completed · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2018–2024
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Site PI · Recruiting · Phase 1, Phase 2
IDEAYA Biosciences
2019–2027
Tebentafusp-tebn With LDT in Metastatic UM
Sub-investigator · Recruiting · Phase 1, Phase 2
Thomas Jefferson University
2025–2032